These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12019103)

  • 21. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
    Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
    Ahmad Z; Tyagi S; Minkowski A; Peloquin CA; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2013 Jul; 188(1):97-102. PubMed ID: 23593945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?
    Lounis N; Ji B; Truffot-Pernot C; Grosset J
    Antimicrob Agents Chemother; 1997 Mar; 41(3):607-10. PubMed ID: 9056001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
    Ostergaard C; Sørensen TK; Knudsen JD; Frimodt-Møller N
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1706-12. PubMed ID: 9661008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
    Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
    Rodriguez-Cerrato V; McCoig CC; Michelow IC; Ghaffar F; Jafri HS; Hardy RD; Patel C; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3092-7. PubMed ID: 11600361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
    Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
    Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS
    J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide.
    Shalit I; Horev-Azaria L; Fabian I; Blau H; Kariv N; Shechtman I; Alteraz H; Kletter Y
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2442-9. PubMed ID: 12121916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
    JI B; Lounis N; Truffot-Pernot C; Grosset J
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1341-4. PubMed ID: 7574527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
    Andries K; Gevers T; Lounis N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.